Stock Analysis
Glaukos CorporationGKOS
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy21 analystsPrice is 78% of the way from the year's low to its high.
PMP Verdict
Weak fundamentals, expensive
Risks
- Valuation25
- Profitability0
Weak fundamentals at a demanding price.
Bull Case
- ✓Altman Z 22.7 — safe-zone balance sheet
- ✓Revenue CAGR 14.6% — durable top-line growth
What's happening with GKOS
Profile
profitability, growth, valuation, moat and earnings quality lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-0.1%)0/25
- P/S (15.9x)5/25
- EV/EBIT (n/a)10/25
- Growth20/100 · Weak
- Revenue CAGR (14.6%)20/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-27.0%)0/25
- ROE (-28.7%)0/25
- Net margin (-30.7%)0/25
- Operating margin (-31.6%)0/25
- Financial Health50/100 · Moderate
- Altman Z (22.70)25/25
- Current ratio (4.69)25/25
- Interest coverage (-11.3x)0/25
- Net cash / debt (n/a)0/25
- Quality30/100 · Weak
- Piotroski F (2/9)5/25
- Beneish M (-3.16)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 25.9%)0/25
- Moat25/100 · Weak
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (76.7%)25/25
- FCF-positive years (3/10 yrs)0/25
- Worst-year net margin (worst -53.5%)0/25
Risk Flags
- ⚠Negative FCF margin (-0.0%) — burning cash
- ⚠SBC 13.1% of revenue — real dilution cost
- ⚠8 loss-making years in recent history
- ⚠Interest coverage -11.3× — thin debt cushion
About Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. Show more
It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Headquarters: ALISO VIEJO, CA · Employees: 1,094 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF610.4xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-0.1%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -4.8%–0.0% · 87th pct
P/S (TTM)15.86xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 5.9x–23.6x · 80th pct
EV/EBITDA3049.6xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales15.9xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio14.81xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.52A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-27.0%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-28.7%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-20.3%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-30.7%D
Grade D: LowNet Income / Revenue
Operating Margin-31.6%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin60.7%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-2.0%D
Grade D: LowFCF / Revenue
True FCF Margin-15.1%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
20ERevenue CAGR14.6%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue13.1%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
50CAltman Z-Score22.70A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.69xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.15xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-11.3xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.10xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
30DPiotroski F-Score2/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score-3.16A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability25.9%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue1.8%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.66xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -312 | |
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -327 | |
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -888 | |
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -1083 | |
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -229 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -136 | |
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -167 | |
Navratil Tomas Filed | Navratil Tomas | SellOpen market sale | -4 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)76.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years3/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-53.5%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$4.86
Cash & short-term investments per share (Finnhub)
Book Value / Share$11.60
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$90.81M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$656.15M
Shareholders' equity (book value)
Asset / Liability3.76xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$9.72B
Current Market Capitalization
Beta0.73B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Glaukos Corporation (GKOS)
Glaukos Corporation meets only 2 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 22.70 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -3.16 suggests a low likelihood of earnings manipulation. Free-cash-flow margin is negative (-2%) — the business currently burns cash.
- Interest coverage of -11.3× leaves little room for earnings shocks.
- Glaukos Corporation posted a net loss in 8 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 25/100, GKOS trades at a premium to its historical multiples.
See how GKOS ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all GKOS moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 8 | Regular | 160.56 | -6.75% | -2.81 |
| Oct 8 | After-hours | 161.29 | -6.32% | -2.63 |
| Oct 7 | Regular | 170.66 | +5.61% | 2.62 |
| Oct 7 | After-hours | 173.55 | +7.40% | 3.35 |
Frequently Asked Questions about GKOS
What is the current Glaukos Corporation (GKOS) stock price?
GKOS is trading at $164.84 at the last market close, down 0.46% on the session. PreMarketPrice tracks GKOS pre-market, intraday and after-hours prices.
Is GKOS stock a buy right now?
PreMarketPrice's quantitative model rates Glaukos Corporation's financial health at 50/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is GKOS stock overvalued?
Glaukos Corporation trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Glaukos Corporation report earnings?
No confirmed earnings date is currently scheduled for GKOS. The Earnings section lists recent reports and updates as dates are announced.
What sector does Glaukos Corporation operate in?
Glaukos Corporation operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Glaukos Corporation do?
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases.
About Glaukos Corporation (GKOS) Stock
Glaukos Corporation (GKOS) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Glaukos Corporation is trading at $164.84, down 0.46% on the day with a market capitalization of $9.7 billion. The financial health score for GKOS is 50/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for GKOS stock.
GKOS Stock Analysis & Key Metrics
On PreMarketPrice, you can track Glaukos Corporation (GKOS) across multiple dimensions:
- Pre-market price & movement: Real-time GKOS stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for GKOS with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Glaukos Corporation across multiple reporting periods.
- Financial health score: A composite score of 50/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for GKOS.
- Sector peers: Compare GKOS against 6 other healthcare stocks on key financial metrics.
Is GKOS a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Glaukos Corporation (GKOS) as an investment. The financial health score of 50/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Glaukos Corporation (GKOS) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.